Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

217 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effective treatment of steroid and therapy-refractory acute graft-versus-host disease with a novel mesenchymal stromal cell product (MSC-FFM).
Bader P, Kuçi Z, Bakhtiar S, Basu O, Bug G, Dennis M, Greil J, Barta A, Kállay KM, Lang P, Lucchini G, Pol R, Schulz A, Sykora KW, von Luettichau I, Herter-Sprie G, Uddin MA, Jenkin P, Alsultan A, Buechner J, Stein J, Kelemen A, Jarisch A, Soerensen J, Salzmann-Manrique E, Hutter M, Schäfer R, Seifried E, Klingebiel T, Bonig H, Kuçi S. Bader P, et al. Among authors: barta a. Bone Marrow Transplant. 2018 Jul;53(7):852-862. doi: 10.1038/s41409-018-0102-z. Epub 2018 Jan 29. Bone Marrow Transplant. 2018. PMID: 29379171 Free PMC article.
Children and Adults with Refractory Acute Graft-versus-Host Disease Respond to Treatment with the Mesenchymal Stromal Cell Preparation "MSC-FFM"-Outcome Report of 92 Patients.
Bonig H, Kuçi Z, Kuçi S, Bakhtiar S, Basu O, Bug G, Dennis M, Greil J, Barta A, Kállay KM, Lang P, Lucchini G, Pol R, Schulz A, Sykora KW, Teichert von Luettichau I, Herter-Sprie G, Ashab Uddin M, Jenkin P, Alsultan A, Buechner J, Stein J, Kelemen A, Jarisch A, Soerensen J, Salzmann-Manrique E, Hutter M, Schäfer R, Seifried E, Paneesha S, Novitzky-Basso I, Gefen A, Nevo N, Beutel G, Schlegel PG, Klingebiel T, Bader P. Bonig H, et al. Among authors: barta a. Cells. 2019 Dec 5;8(12):1577. doi: 10.3390/cells8121577. Cells. 2019. PMID: 31817480 Free PMC article.
The potential role of HLA-DRB1*11 in the development and outcome of haematopoietic stem cell transplantation-associated thrombotic microangiopathy.
Balassa K, Andrikovics H, Remenyi P, Batai A, Bors A, Kiss KP, Szilvasi A, Rajczy K, Inotai D, Gopcsa L, Lengyel L, Barta A, Reti M, Tordai A, Masszi T. Balassa K, et al. Among authors: barta a. Bone Marrow Transplant. 2015 Oct;50(10):1321-5. doi: 10.1038/bmt.2015.161. Epub 2015 Jul 6. Bone Marrow Transplant. 2015. PMID: 26146809
Recipient and donor JAK2 46/1 haplotypes are associated with acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.
Balassa K, Krahling T, Remenyi P, Batai A, Bors A, Kiss KP, Torbagyi E, Gopcsa L, Lengyel L, Barta A, Varga G, Tordai A, Masszi T, Andrikovics H. Balassa K, et al. Among authors: barta a. Leuk Lymphoma. 2017 Feb;58(2):391-398. doi: 10.1080/10428194.2016.1198956. Epub 2016 Jul 7. Leuk Lymphoma. 2017. PMID: 27389386
Early Versus Delayed Autologous Stem Cell Transplantation and Interferon Maintenance in Multiple Myeloma: Single-Center Experience of 18 Years.
Remenyi P, Varga G, Mikala G, Reti M, Gopcsa L, Batai A, Csukly Z, Lengyel L, Torbagyi E, Barta A, Fabian J, Levai D, Szombath G, Andrikovics H, Masszi T. Remenyi P, et al. Among authors: barta a. Transplant Proc. 2016 Jan-Feb;48(1):177-84. doi: 10.1016/j.transproceed.2015.12.031. Transplant Proc. 2016. PMID: 26915865
Remarkably reduced transplant-related complications by dibromomannitol non-myeloablative conditioning before allogeneic bone marrow transplantation in chronic myeloid leukemia.
Barta A, Dénes R, Masszi T, Reményi P, Bátai A, Torbágyi E, Sipos A, Lengyel L, Jakab K, Gyódi E, Réti M, Földi J, Páldi-Haris P, Avalos M, Pálóczi K, Fekete S, Török J, Hoffer I, Jakab J, Váradi G, Kelemen E, Petrányi G. Barta A, et al. Acta Haematol. 2001;105(2):64-70. doi: 10.1159/000046536. Acta Haematol. 2001. PMID: 11408706 Clinical Trial.
Donor KIR2DS1 reduces the risk of transplant related mortality in HLA-C2 positive young recipients with hematological malignancies treated by myeloablative conditioning.
Tordai A, Bors A, Kiss KP, Balassa K, Andrikovics H, Batai A, Szilvasi A, Rajczy K, Inotai D, Torbagyi E, Lengyel L, Barta A, Remenyi P, Masszi T. Tordai A, et al. Among authors: barta a. PLoS One. 2019 Jun 25;14(6):e0218945. doi: 10.1371/journal.pone.0218945. eCollection 2019. PLoS One. 2019. PMID: 31237928 Free PMC article.
217 results